Skip to Main Content

Author Details

David E Neal
University of Oxford, John Radcliffe Hospital
1981
586
99
PMIDPaper TitleJournal TitlePublished Year
36912538Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.N Engl J Med2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
37292833Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry.medRxiv2023
37311464Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry.Am J Hum Genet2023
37296430Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).BMC Health Serv Res2023
34599350A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.World J Urol2022
36201131Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.Pharmacoeconomics2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
33473200Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33623038Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.Nat Commun2021
33580906Identification of a serum biomarker signature associated with metastatic prostate cancer.Proteomics Clin Appl2021
34469575Correction to 'Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation'.Nucleic Acids Res2021
33436325Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.Eur Urol Oncol2021
33398198Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nat Genet2021
33420416Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.Prostate Cancer Prostatic Dis2021
32450824Independence of HIF1a and androgen signaling pathways in prostate cancer.BMC Cancer2020
34337468Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification.Eur Urol Open Sci2020
33158149The <i>CHEK2</i> Variant C.349A&gt;G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor.Cancers (Basel)2020
32773013Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health Technol Assess2020
32624282Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].Eur Urol2020
32907896Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.BMJ Open2020
32514134The effect of sample size on polygenic hazard models for prostate cancer.Eur J Hum Genet2020
30622367Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2019
35047778Precision prostatectomy: reconciling functional and oncological outcomes.BMJ Surg Interv Health Technol2019
30237440A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.Oncogene2019
31548585Publisher Correction: Shared heritability and functional enrichment across six solid cancers.Nat Commun2019
30777372Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.Eur Urol2019
30921005Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial.Eur J Cancer Prev2019
30873591The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.Int J Cancer2019
30683880Shared heritability and functional enrichment across six solid cancers.Nat Commun2019
30425058A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.Cancer Res2019
30597039Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study.Int J Epidemiol2019
28753852DESNT: A Poor Prognosis Category of Human Prostate Cancer.Eur Urol Focus2018
29892050Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.Nat Commun2018
29892016Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.Nat Genet2018
29878078AA9int: SNP interaction pattern search using non-hierarchical additive model set.Bioinformatics2018
30397198Germline variation at 8q24 and prostate cancer risk in men of European ancestry.Nat Commun2018
30309839ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.Cancer Prev Res (Phila)2018
29729848Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer.EBioMedicine2018
29353635Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV).Eur J Oncol Nurs2018
29662167Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.Nat Genet2018
29438364Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.Br J Cancer2018
29438362Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.Br J Cancer2018
29437778Identification of potential therapeutic targets in prostate cancer through a cross-species approach.EMBO Mol Med2018
29509864Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.JAMA2018
29453511Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer.Cancer Causes Control2018
29366640Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.J Urol2018
29288137A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.J Clin Epidemiol2018
29278842Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.Cancer Epidemiol2018
29321194Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.BMJ2018
  • 1 - 50 of 586

Recommended Authors

University of Texas Health San Antonio
Career Start Year 2008
Number of shared co-authors 11
Mount Sinai Hospital, University of Toronto, University Health Network
Career Start Year 2007
Number of shared co-authors 16
University of Alberta
Career Start Year 2007
Number of shared co-authors 5
Peter MacCallum Cancer Centre, University of Melbourne
Career Start Year 2005
Number of shared co-authors 50
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 27
University of California San Diego
Career Start Year 2005
Number of shared co-authors 4
Queen's University
Career Start Year 1996
Number of shared co-authors 15
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 23
New York-Presbyterian Hospital
Career Start Year 1994
Number of shared co-authors 18
University Health Network, Princess Margaret Cancer Center, University of Toronto
Career Start Year 1993
Number of shared co-authors 28
The Institute of Cancer Research
Career Start Year 1993
Number of shared co-authors 37
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 14
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 18
Hospitalier Universitaire de Saint-Etienne
Career Start Year 1989
Number of shared co-authors 21
University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Career Start Year 1989
Number of shared co-authors 4
University of California Davis
Career Start Year 1988
Number of shared co-authors 35
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 14
Monash University
Career Start Year 1988
Number of shared co-authors 36
University of Melbourne
Career Start Year 1988
Number of shared co-authors 24
Amsterdam University Medical Centers, University of Amsterdam
Career Start Year 1987
Number of shared co-authors 11
PolyClinic St. Moritz/Scuol
Career Start Year 1986
Number of shared co-authors 11
Eberhard Karls University of Tubingen
Career Start Year 1984
Number of shared co-authors 23
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 33
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 19
University Hospitals Leuven
Career Start Year 1981
Number of shared co-authors 25
Mayo Clinic
Career Start Year 1980
Number of shared co-authors 12
University of Washington School of Medicine
Career Start Year 1980
Number of shared co-authors 27
Rutgers Cancer Institute of New Jersey
Career Start Year 1975
Number of shared co-authors 8
Mayo Clinic College of Medicine
Career Start Year 1973
Number of shared co-authors 10
Martini-Klinik Prostate Cancer Center, University Hospital-Hamburg-Eppendorf
Career Start Year 1971
Number of shared co-authors 11

Collaborators

University of Oxford
Co-authored papers 217
The Institute of Cancer Research
Co-authored papers 76
The Institute of Cancer Research
Co-authored papers 70
University of Cambridge
Co-authored papers 67
Cambridge University Hospitals National Health Service Foundation Trust
Co-authored papers 57
Co-authored papers 48
Karolinska Institute
Co-authored papers 48
Co-authored papers 45
Co-authored papers 43
Fred Hutchinson Cancer Research Center
Co-authored papers 41
Institute of Biomedicine, University of Turku
Co-authored papers 41
Queen's University Belfast
Co-authored papers 40
University of Southern California
Co-authored papers 40
Co-authored papers 39
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 38
Mayo Clinic
Co-authored papers 37
Co-authored papers 36
University College London
Co-authored papers 31
Co-authored papers 30
University of Cambridge
Co-authored papers 29
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 29
Co-authored papers 28
University of Cambridge
Co-authored papers 28
Oncogenetics Team The Institute of Cancer Research London UK.
Co-authored papers 26
Co-authored papers 25
Co-authored papers 25
Co-authored papers 24
National Cancer Institute, National Institutes of Health
Co-authored papers 23
The Institute of Cancer Research
Co-authored papers 23
Co-authored papers 23